SOHO state of the art updates and next questions: Update on tailoring therapy in T cell lymphomas Review
| Authors: | Moe, C.; Zain, J. |
| Review Title: | SOHO state of the art updates and next questions: Update on tailoring therapy in T cell lymphomas |
| Abstract: | Peripheral T cell lymphomas are rare and heterogenous diseases with no clear curative options in the relapsed setting. Treatments based on paradigms for aggressive B cell lymphomas have yielded poor outcomes and there is an immense need for therapies that are directed towards PTCL. Understanding the biology and pathologic pathways for this group of diseases has allowed the development of more specific targeted therapies. The are initially evaluated in the relapsed setting with the hope that these agents will then be combined with more traditional lymphoma directed therapies for improved outcomes. This approach has also elucidated that PTCL subtypes differ in biology and treatments should be tailored depending accordingly. © 2025 |
| Keywords: | histone deacetylase inhibitor; review; nonhuman; side effect; phase 2 clinical trial; peripheral t cell lymphoma; t cell lymphoma; drug combination; phase 1 clinical trial; drug administration; drug therapy; adverse drug reaction; therapy; pharmacology; phosphatidylinositol 3 kinase inhibitor; hdac inhibitors; drug comparison; brentuximab vedotin; human; hypomethylating agents; pi3 kinase inhibitor; aggressive b cell non hodgkin lymphoma; relapsed ptcl- |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 25 |
| Issue: | 9 |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Publication status: | Published |
| Date Published: | 2025-09-01 |
| Online Publication Date: | 2025-05-18 |
| Start Page: | e656 |
| End Page: | e662 |
| Language: | English |
| DOI: | 10.1016/j.clml.2025.05.009 |
| PROVIDER: | scopus |
| PUBMED: | 40518373 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
